The amino acid transporter SLC7A11 expression in breast cancer

ABSTRACT Breast cancer (BC), characterized by its diverse molecular profiles and clinical outcomes, presents a significant challenge in the development of effective therapeutic strategies. Metabolic reprogramming, a defining characteristic of cancer, has emerged as a promising target for novel therapies. SLC7A11, an amino acid transporter that facilitates cysteine uptake in exchange for glutamate, plays a crucial role in sustaining the altered metabolism of cancer cells. This study delves into the comprehensive analysis of SLC7A11 at the genomic, transcriptomic, and protein levels in extensive BC datasets to elucidate its potential role in different BC subtypes. SLC7A11 gene copy number and mRNA expression were evaluated using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort (n = 1,980) and Breast Cancer Gene Expression Miner (n = 4,712). SLC7A11 protein was assessed using immunohistochemistry in a large BC cohort (n = 1,981). Additionally, The Cancer Genome Atlas (TCGA) dataset was used to explore SLC7A11 DNA methylation patterns using MethSurv (n = 782) and association of SLC7A11 mRNA expression with immune infiltrates using TIMER (n = 1,100). High SLC7A11 mRNA and SLC7A11 protein expression were significantly associated with high tumor grade (p ≤ .02), indicating a potential role in cancer progression. Interestingly, SLC7A11 copy number gain was observed in HER2+ tumors (p = .01), suggesting a subtype-specific association. In contrast, SLC7A11 mRNA expression was higher in the basal-like/triple-negative (TN; p < .001) and luminal B tumors (p = .02), highlighting its differential expression across BC subtypes. Notably, high SLC7A11 protein expression was predominantly observed in Estrogen Receptor (ER)-negative and Triple Negative (TN) BC, suggesting a role in these aggressive subtypes. Further analysis revealed that SLC7A11 was positively correlated with other amino acid transporters and enzymes associated with glutamine metabolism, implying a coordinated role in metabolic regulation. Additionally, SLC7A11 gene expression was positively associated with neutrophil and macrophage infiltration, suggesting a potential link between SLC7A11 and tumor immunity. Our findings suggest that SLC7A11 plays a significant role in BC metabolism, demonstrating differential expression across subtypes and associations with poor patient outcomes. Further functional studies are warranted to elucidate the precise mechanisms by which SLC7A11 contributes to BC progression and to explore its potential as a therapeutic target.


Introduction
Breast cancer (BC), the top malignancy in women, 1 is a heterogeneous disease with various biological subtypes that differ in morphology, biological subtypes, response to therapy and clinical behavior. 2This variability further underscores the notion of varying cancer hallmarks and drivers within the different subtypes of breast cancer.
Metabolic reprogramming ensures tumors have a sufficient supply of nutrients to support their rapid growth and proliferation, playing a central role in energy production and biosynthesis. 3This altered metabolism likely contributes to tumor progression and therapeutic failure, which further reinforces the importance of novel therapeutic strategies targeting metabolic reprogramming.Glutamine metabolism is a particular focus of attention as cancer cells can be heavily dependent on this most abundant, non-essential amino acid for nutritional uptake fueling cancer cell unremitted growth. 4utamine metabolism and associated metabolic networks including expression of related amino acid transporters are essential for cancer cell survival. 5Rapidly proliferating cancer cells take up glutamine via these amino acid transporters and subsequently transform it into glutamate by glutaminase, a process called glutaminolysis. 6This intracellular glutamate is exchanged with extracellular cystine, the oxidized dimer form of cysteine, at a ratio of 1:1 through Solute Carrier Family 7 Member 11 (SLC7A11) which is later converted into cysteine.SLC7A11 is a sodium independent, chloridedependent anionic L-cystine/L-glutamate antiporter on the cell surface. 7[10] However, in oxidative stress, de novo biosynthesis or a catabolic supply of cysteine is not sufficient to meet the high requirement for antioxidant synthesis by cancer cells.Hence, most rely on amino acid transporters, such as SLC7A11, that can import extracellular cystine 8 and thus metabolic reprogramming orchestrates the energy supply reflecting the altered metabolic needs of tumors. 11LC7A11 mediated cystine uptake plays a positive but rate limiting role in glutathione synthesis, contributing to the pathogenesis of cancer where glutathione activates the antioxidant defense machinery that protects cancer cells from apoptosis, oxidative stress and ferroptosis. 7,9,12,135][16][17][18][19][20][21][22][23] The opposing expression levels between normal and cancer cell suggest the SLC7A11 could act as a potential target for cancer treatment.In BC, SLC7A11 is suggested to play a crucial role in cancer stem cells impacting metastasis. 24In TNBC, the most aggressive biological subtype with poor survival, it also plays an important role in disease progression and proliferation. 25,26iven the diverse origins and divergent disease progression of breast cancer (BC) subtypes, these subtypes are likely to possess distinct genomic, transcriptomic, and proteomic alterations that influence clinical outcomes and treatment responses.8][29] Therefore, it is hypothesized that SLC7A11 expression also exhibits heterogeneity in BC, leading to varying outcomes across different subtypes.This prompted a comprehensive investigation to assess the impact of SLC7A11 in BC, evaluating its transcriptomic and proteomic expression in BC subtypes as a potential prognostic marker.
Staining of SLC7A11 in full-face BC tissue sections demonstrated a homogenous pattern of immunoreactivity.SLC7A11 protein expression was mainly observed in the cytoplasm of the invasive breast tumor cells, with intensity levels varying from absent to high (Figure 1).The distribution of SLC7A11 expression was unimodal and left-skewed and X-tile software was used to identify the optimal cutoff point in predicting breast cancer specific survival (BCSS).High SLC7A11 protein (>100 H-score) was observed in 784/1,981 (40%) of cases.

SLC7A11 DNA methylation in breast cancer
Several CpG islands showed high SLC17A11 DNA methylation within the genomic body of the gene including cg21877274 and cg24869834 (Supplementary Figure S2).The first exon in the 5' untranslated region showed little methylation.

Association of SLC7A11 expression with clinicopathological characteristics
Within the METABRIC cohort, SLC7A11 CN gain was significantly associated with invasive breast carcinoma of no special type (NST) (p = .0002;Table 1).High SLC7A11 mRNA expression was associated with high tumor grade (p = .01,Figure 2b) but not with tumor size or nodal stage (Figure 2a,c).Within the Breast Cancer Gene-Expression Miner dataset, SLC7A11 mRNA expression was significantly associated with higher tumor grade, lymph node negative tumors, and high NPI (all p ≤ .0005;Supplementary Figure S3a-c).At the protein level, high SLC7A11 was significantly associated with both high and low tumor grade (p = .02,Table 2) which was reflected in its separate components where it was associated with high mitotic count (p = .02,Table 2) and high pleomorphism (p = .002,Table 2) but in contrast also showed association with tubule formation (p = .007;Table 2).High SLC7A1l was further significantly associated with special and tubular histological types (p = .005;Table 2).There was no association between SLC7A11 with tumor size, nodal stage, or NPI.

Association of SLC7A11 expression with immune infiltration
Using the TIMER dataset, SLC7A11 gene expression was positively associated, albeit weakly, in breast tumors with neutrophil (p = 2.0×10 −24 ) and macrophage (p = 4.5×10 −6 ) infiltration (Table 4).HER2+, luminal A and luminal B tumors also showed a weak to moderate correlation between SLC7A11 mRNA with neutrophil and macrophage infiltration (p ≤ .009,Table 4).A weak negative correlation between SLC7A11 mRNA and CD4+ immune cells was observed in HER2+, luminal A and luminal B tumors (p ≤ .037,Table 4).SLC7A11 CN gain or loss were not associated with immune cell infiltrates in BC or any subtype (data not shown).

SLC7A11 expression and other associated genes
The METABRIC dataset was used to investigate the correlation between SLC7A11 mRNA and the expression of other associated genes (Table 5).1][32][33] There was a positive correlation between SLC7A11 mRNA expression and the expression of the regulatory gene, ATF4 (p = .004,Table 5).SLC7A11 was also positively correlated with the ancillary genes, SLC3A2 and CD44 (all p ≤ .01,Table 5).While the former was associated within all molecular subtypes (all p ≤ .03,Table 5) except HER2+, correlation with CD44 was only observed within luminal B tumors (p = .03,Table 5).Whilst there was a positive correlation observed between SLC7A11 with the high glutamine affinity solute carriers SLC1A5 and SLC7A5 (all p ≤ .001,Table 5).There were no significant associations with other glutamine affinity solute carriers SLC7A8 or SLC38A2.Likewise, there was no association between SLC7A11 and the glutamate transporters SLC1A3, SLC1A6 and SLC1A7 or the cystine/glutamate antiporter SLC1A1.There was, however, a positive association between SLC7A11 and SLC1A2 (p = .04,Table 5) which lost its significance when the different BC subtypes were examined separately.The association of SLC7A11 protein expression with other associated proteins was also examined (Table 6).At the protein level, SLC7A11 was significantly expressed with breast tumors that expressed high MYC, Ki67, and Glutaminase (GLS; all p ≤ .01,Table 6).There was no significant association between SLC7A11 and Glutamate Dehydrogenase (GLUD1) (p > .05,Table 6), the enzyme which degrades glutamate to α-ketoglutarate.Nonetheless, a positive association was observed with SLC7A11 and SLC1A5, SLC7A5, SLC7A8, SLC3A2 and SLC38A2 (all p ≤ .04,Table 6).Moreover, SLC7A11 was highly expressed in BCs which express high p53 protein (p = .01,Table 6).

Association of SLC7A11 and patient outcome
Survival analysis of high SLC7A11 mRNA was significantly associated with shorter BCSS (p = .02,Figure 3a).Multivariate analysis showed that SLC7A11 mRNA was a predictive of poor survival independent of tumor grade, tumor size, and lymph node stage (p = .008,Table 7) and the result remained significant within the luminal A tumors (p = .02,Table 7).The relationships between SLC7A11 mRNA expression and patient outcome were verified using Breast Cancer Gene-Expression Miner (Supplementary Figure S4).High SLC7A11 mRNA expression showed association with shorter overall survival (OS) in all cases (p = .0004,Supplementary Figure S4a) and in HER2+ cases (p = .02,Supplementary Figure S4e).In contrast, SLC7A11 protein was not associated with patient outcome, in terms of BCSS and DMFS either in the whole cohort or when the different BC subtypes were examined (Figure 4).High SLC7A11 mRNA expression showed association with shorter OS (p = 3.6×10-5, Supplementary Figure S5a) in the KM plotter dataset whereas no significance was found in terms of SLC7A11 protein expression (Supplementary Figure S5b).DNA methylation of both cg21877274 and cg24869834 CpG sites on SLC7A11 correlated with poorer patient survival rates (p = .0014and p = .0074respectively; Supplementary Figure S2b,c).

Discussion
BC is a biologically heterogeneous disease 34 with various molecular subtypes that influences its metabolic programming and nutritional needs for its growth and proliferation, which can ultimately affect patient survival.Thus, understanding the metabolic profiling along with their biological characteristics could help to identify potential therapeutic targets and prognostic markers.The present study explored SLC7A11 expression in BC by assessing its genomic, transcriptomic, and proteomic levels for the first time in several large breast cancer cohorts.It revealed that SLC7A11 could potentially play a significant role in BC subtypes influencing the patient outcome.
In this study, we show SLC7A11 CN loss was more common than CN gain which was generally associated with a small number of HER2+ cases.However, there was no association between SLC7A11 CNV and mRNA expression, suggesting that CN gain does not contribute to SLC7A11 transcription or SLC7A11 translation.SLC7A11 mRNA and SLC7A11 protein expression were primarily associated with poor clinicopathological parameters and SLC7A11 DNA methylated predicted poor patient survival.Further analysis revealed that SLC7A11 was positively correlated with other amino acid transporters and enzymes associated with glutamine metabolism, implying a coordinated role in metabolic regulation.Additionally, SLC7A11 gene expression was positively associated with neutrophil and macrophage infiltration, suggesting a potential link between SLC7A11 and tumor immunity.
While focusing on BC subtypes, the poor prognostic ER negative and TNBC showed high SLC7A11 mRNA and SLC7A11 protein expression.This relation was supported by a previous study where Timmerman et al 26 reported that SLC7A11 is significantly expressed in TNBC.TNBC tend to act as a glutamine auxotroph, which correlates SCL7A11 and cystine consumption.This potentially indicates that TNBC with high SLC7A11 expression can show an aggressive BC advancement.TNBC currently as only chemotherapy as its treatment option due to the absence of growth in response to hormones and SLC7A11 is found to modulate chemotherapy or vice versa. 35,36Cancer cells are rendered more resistant to chemotherapy if SLC7A11 is overexpressed. 37This supports the fact that SLC7A11 can represent itself as a potential target to observe it as a treatment response factor in TNBC and such suggestions were backed by earlier studies. 25,35,38egarding exploring the additional genes associated with SLC7A11, transcription factor ATF4 was significantly associated with SLC7A11 mRNA.0][41] AFT4 regulates redox homeostasis and amino acid metabolism. 38As a part of redox homeostasis in the cancer cell, SLC7A11 presence contributes to increasing glutathione, which later promotes metabolic reprogramming.This supports the notion that under stress condition; proteasome inhibition or glucose starvation, SLC7A11 requires ATF4 for its expression. 402][43] Hereby, SLC7A11 is also influenced by CD44, the adhesion molecule, which stabilizes SLC7A11 which subsequently promotes the uptake of cystine for glutathione synthesis, 33 which is further supported by the fact that CD44 deficiency can result into intracellular glutathione depletion 43 resulting in ROS induction, inhibiting tumor formation and inducing ferroptosis.[46]  This study further investigated the association of SLC7A11 expression with other glutamine transporters.SLC7A11 was strongly associated with SLC3A2, SLC1A5, SLC7A5, and SLC38A2, which reinforces that amino acid transporter activity is altered to meet the altered environment in BC.SLC3A2 is required for SLC7A11 for its optimum activation, where SLC7A11 heterodimerises with SLC3A2 via a disulfide bridge.8][49] SLC3A2 absence also brings a substantial decrease of SLC7A11 activity indicating a crucial role for SLC7A11 stability. 50,51ur study also showed SLC7A11 protein was strongly associated with GLS expression, the key enzyme for glutamine catabolism in line with an earlier study. 52GLS activity is paused by the presence of sufficient intracellular glutamate but the high expression of SLC7A11, which decreases the cellular glutamate by exporting, potentially reactivate GLS activity through negative feedback contributing to cell nutrient supply, especially in TNBC. 53Thus, the combination of GLS and SLC7A11 inhibitors can offer a potential treatment approach for TNBC.
In BC, MYC and TP53 genes are altered and have direct role on BC prognosis and treatment options. 54c-Myc has a direct role in glutamate metabolism 55 and SLC7A11 is directly induced by c-Myc, or vice versa, and our results support this association.In addition, p53 protein (encoded by TP53) is strongly associated with SLC7A11 18 and p53 mutations alter SLC7A11 expression. 51,56p53 also acts upon glutathione synthesis, which is mediated by SLC7A11, when tumor cells are serine starved, thus preserving cellular anti-oxidant capacity. 57p53 also negatively regulates SLC7A11 and as p53 is considered a pro-ferroptotic factor, it can increase the sensitivity to ferroptosis. 31Furthermore, high SLC7A11 expression was significantly associated with Ki67 reinforcing previous studies. 18,58Since Ki67 is a poor prognostic biomarker in invasive breast cancer, 59 its positive association with SLC7A11 depicts the fact that subtype with overexpression of SLC7A11 can demonstrate aggressive disease progression.
SLC7A11 mRNA was correlated with the infiltration levels of neutrophils and macrophages irrespective of biological subtype.Neutrophils, believed to promote metastasis in BC, 60 can affect intracellular GSH levels and thus can influence SLC7A11 activity. 61Macrophages are thought to participate in ferroptosis 62 and SLC7A11 could act as a connection between the two.High presence of these immune cells can potentially offer a synergistic impact for BC treatment focusing on SLC7A11.
Whilst high SLC7A11 mRNA was an independent predictor of poor OS all cases and in luminal A tumors this was not translated into protein expression.4][65][66][67] Transcriptional process and mRNA decaying process can lead discordance between protein and mRNA expression.SLC7A11 mRNA has a relation with SLC3A2 and CD44 which can also affect its protein stability, so these regulatory mechanisms require further investigation.
In conclusion, this study revealed a robust characterization of the glutamate/cysteine transporter SLC7A11 as an independent prognostic factor in BC.Several SLC and other factors associated with the glutamate transport axis were related to SLC7A11 and their combined functionality gives opportunities to explore them as potential therapeutic targets.Further functionals studies on SLC7A11 in BC are therefore warranted.

SLC7A11 genomic and transcriptomic expression
SLC7A11 CNV and mRNA expression were evaluated in a cohort of 1,980 BC tumors in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). 68he METABRIC study provides genomic and transcriptional profiling data on BC using the Affymetrix SNP 6.0 and Illumina HT-12v3 platforms, respectively.In this cohort, patients enrolled as ER-and lymph node (LN) positive received adjuvant treatment while patients with ER+ and/or LN negative did not receive adjuvant chemotherapy.Dichotomization of SLC7A11 mRNA expression was conducted using X-tile (version 3.6.1,Yale University, USA), based on the prediction of Breast Cancer Specific Survival (BCSS).Association of CNV including loss and gain and mRNA expression along with clinicopathological parameters and molecular subtypes were investigated.mRNA expression with other genes related to glutamine metabolism and patient's survival were also investigated.To validate SLC7A11 mRNA expression, Breast Cancer Gene Expression Miner v4.5 (bcgenex.centregauducheau.fr)incorporating The Cancer Genome Atlas (TCGA) and SCAN-B RNA sequencing data (n = 4,712) and Kaplan-Meier Plotter database (RNA-seq data for breast cancer) (n = 2976) were used as external validation datasets.
SLC7A11 CNV (n = 1080) and mRNA (n = 1100) expression were also investigated in BC using TIMER (http://timer.cistrome.org/) to estimate the abundance of SLC7A11 in six subsets (B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells). 69MethSurv (biit.cs.ut.ee/methsurv) was used to explore the DNA methylation of SLC7A11 in the TCGA data according to patient survival. 70DNA methylation status was dichotomized using the 'best' option.neoadjuvant therapy.Clinical history, tumor characteristics, information on therapy and outcomes were prospectively maintained.Outcome data including development and time to distant metastasis (DM) and BCSS.DM-free survival (DMFS) was defined as the time (in months) from the date of primary surgery to the appearance of DM.The BCSS was defined as the time (in months) from the date of primary surgery to the date of BC-related death.SLC7A11 protein expression was correlated with clinicopathological parameters, BC subtypes, other genes related to glutamine metabolism and patient's survival.The Kaplan-Meier Plotter database (protein data for breast cancer) (n = 1064) was used as an external validation dataset.

Tissue microarrays and IHC
Tissue Microarrays (TMAs) were produced following standard techniques as described. 71Polymer-based IHC was performed on 4 µm thick section using the Novolink Polymer Detection System (Leica Biosystems, RE7150-K) according to the manufacturer's instructions.Heat mediated antigen retrieval was carried out using citrate buffer at pH 6.0.SLC7A11 antibody was used at a 1:50 dilution for 1 hour at room temperature.Beta2-microglobulin at a concentration of 1:2,000 was used as a positive control.

Assessment of SLC7A11 protein expression
Stained TMA sections were assessed using high resolution digital images (NanoZoomer, Hamamatsu Photonics, Welwyn Garden City, UK) at 20× magnification viewed using Philips Xplore software (Philips Digital Pathology Solutions, Amsterdam, Netherlands).Assessment of protein staining was based on a semi-quantitative H-Score which includes an assessment of both intensity of staining and percentage of stained cells. 72Adequate tumor burden was assessed ensuring that the TMA core contained more than 15% of invasive tumor (excluding DCIS).Intensity of the staining ranged from a scale of 0 to 3 (0 = no staining, 1= weak, 2 = moderate, 3 = strong) and the percentage of positively stained invasive BC cells was estimated subjectively.A final H-score of 0-300 was generated based on % of cells stained at each intensity.A second observer blindly scored 10% cores to assess scoring ability and concordance.There was high interobserver concordance between the scorers (Kappa score = 0.64).Dichotomization of SLC7A11 protein expression was determined based on the prediction of BCSS using X-tile software.

Statistical analysis
Statistical analysis was performed using SPSS 22 statistical software (SPSS Inc., Chicago, IL, USA).Chi-square test was performed to analyze categorical variables.For continuous variables, Pearson correlation coefficient was used to test correlation between two continuous normalized data, whereas the differences between three or more groups were assessed using one-way analysis of variance (ANOVA) with the post-hoc Tukey multiple comparison test.Survival analysis was done using Kaplan-Meier with Log Rank test for outcome.Cox's proportional hazard method was implied to identify independent prognostic factors.P-values were adjusted using Bonferroni correction for multiple testing.Variables with p-values <0.05 were considered statistically significant.

Notes on contributors
Preyanka Nath holds master's degrees from the University of Nottingham, UK, and Brac University, Bangladesh, and a bachelor's degree from the Shahjalal University of Science & Technology in Bangladesh.They are a lecturer at the North South University in Bangladesh.
Lutfi Alfarsi holds a PhD from the University of Nottingham, UK, a bachelor's degree from Manchester Metropolitan University, UK, and a master's degree from Nottingham Trent University, UK.They are a Director of a healthcare provider in Saudi Arabia.
Rokaya El-Ansari holds a PhD from the University of Nottingham, UK, a medical degree from Tripoli University, Libya, and a master's degree from the University of Leicester, UK.They are a histopathologist in the UK.
Brendah Masisi holds a PhD from the University of Nottingham, UK, a master's degree from the University of the West of England, UK, and a bachelor's degree from the University of Botswana, Botswana.They are a lecturer at the University of Botswana.
Busra Erkan is a PhD student at the University of Nottingham, UK.They hold a bachelor's degree from Istanbul Halic University, Turkey, and a master's degree from the University of Leicester, UK.
Ali Fakroun is a PhD student at the University of Nottingham, UK.They hold a bachelor's degree from Cardiff University, Wales, and a master's degree from the University of Nottingham, UK.

Figure 1 .
Figure 1.SLC7A11 protein expression in representative invasive breast cancer tissue microarray cores determined using immunohistochemistry showing a) high, and b) negative expression.Magnification x20.

Figure 2 .
Figure 2. SLC7A11 mRNA expression and its association with clinicopathological parameters and molecular subtypes in the METABRIC cohort: a) SLC7A11 and tumor size, b) SLC7A11 and tumor grade, c) SLC7A11 and lymph node stage, d) SLC7A11 and METABRIC Integrative clusters, e) SLC7A11 and PAM50 subtypes, f) SLC7A11 and ER, g) SLC7A11 and PR, h) SLC7A11 and HER2.

Figure 3 .
Figure 3. SLC7A11 mRNA expression and its association in breast cancer biological subtypes with patient breast cancer specific survival in the METABRIC cohort: a) SLC7A11 in all cases, b) SLC7A11 in luminal A, c) SLC7A11 in luminal B, d) SLC7A11 vs triple Negative, and e) SLC7A11 in HER2+ breast cancer.
CANCER BIOLOGY & THERAPYPatients' cohort for SLC7A11 protein expressionImmunohistochemistry (IHC) was conducted on a wellcharacterized BC series from patients at Nottingham City Hospital during 1987-2006 (n = 1,981).The patients were diagnosed with early-stage primary operable invasive BC and aged ≤70 years.Patient management was uniform and based on tumor characteristics including the Nottingham Prognostic Index (NPI) and hormone receptor status.Patients with NPI > 3.4 received tamoxifen if ER+ (± goserelin, in premenopausal patients).Conversely, classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were used in ER-patients who were fit enough to receive chemotherapy.No patients received

Figure 4 .
Figure 4. SLC7A11 protein expression and its association with patient breast cancer specific survival (BCSS) in the Nottingham cohort: a) SLC7A11 in all cases, b) SLC7A11 in ER+ low proliferative, c) SLC7A11 in ER+ high proliferative, d) SLC7A11 in triple Negative, and e) SLC7A11 in HER2+ breast cancer.
Ellis is a Professor of Cancer Pathology at the University of Nottingham, UK, and Honorary Consultant Pathologist at Nottingham University Hospitals NHS Trust, UK.He is a Past President of the Pathological Society of Great Britain and Ireland.He has been Specialty Advisor to The Royal College of Pathologists, and is past Chairman of the UK National Co-ordinating Committee for Breast Pathology.He has acted as an advisor to the DoH, UICC, WHO, and IARC.Emad Rakha is a Professor of Breast Pathology at the University of Nottingham and Honorary Consultant Pathologist at Nottingham University Hospitals NHS Trust, UK.They hold a PhD from the University of Nottingham.They are co-chair of the UK National Breast Pathology Interpretive Quality Assurance Scheme and General Secretary of the International Society of Breast Pathology.Andrew R. Green is an Associate Professor at the University of Nottingham, UK.They hold a PhD from the University of Hull, UK, and a bachelor's degree from the University of East London, UK.They are Deputy Director of the Nottingham Breast Cancer Research Centre and group leader of the breast cancer metabolism group.

Table 1 .
SLC7A11 copy number variation in the METABRIC breast cancer cohort and their association with clinicopathological parameters and breast cancer subtypes.

Table 2 .
Clinicopathological associations of SLC7A11 protein expression in Nottingham BC cohort.

Table 3 .
Association of SLC7A11 protein expression with breast cancer subtypes in the Nottingham BC cohort.
P-values in bold means statistically significant.

Table 4 .
SLC7A11 gene expression and association with immune infiltrates using timer.

Table 5 .
Correlation of SLC7A11 mRNA expression with the expression of other related genes in the METABRIC cohort.
P values in bold means statistically significant.

Table 6 .
Association of SLC7A11 protein expression and other associated proteins in the Nottingham BC cohort.
P values in bold means statistically significant.

Table 7 .
SLC7A11 mRNA expression and patient outcome in BC molecular subtypes using the METABRIC cohort.